Quality control in multicentric clinical trials. An experience of the EORTC gynecological cancer cooperative group

被引:19
|
作者
Favalli, G
Vermorken, JB
Vantongelen, K
Renard, J
Van Oosterom, AT
Pecorelli, S
机构
[1] Univ Antwerp Hosp, Dept Med Oncol, B-2650 Edegem, Belgium
[2] Univ Brescia, Spedali Civili, Dept Gynecol Oncol, Brescia, Italy
[3] Univ Hosp Gasthuisberg, Dept Oncol, B-3000 Louvain, Belgium
[4] Eortc Data Ctr, Brussels, Belgium
关键词
quality control; multicentric trials; chemotherapy;
D O I
10.1016/S0959-8049(00)00090-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Data Quality is a central requirement of scientific research and external monitoring is essential in multicentric clinical trials (MCT). A quality control (QC) study was conducted in the main Institutions participating in EORTC-GCCG Protocol number 55863 - randomised phase III trial of vindesine. cisplatin, bleomycin and mitomycin-C (BEMP) versus cisplatin (P) in disseminated squamous cell carcinoma of the uterine cervix - in order to assess the impact of variations in data quality on the conclusions of the trial. The reliability of the different centres in following the protocol was investigated by a questionnaire covering drug prescription, local facilities and the procedure for preparation and administration of chemotherapy. The 'treatment protocol adherence' was evaluated by recalculation of the ideal protocol dose and its comparison with the actual delivered dosage at each cycle of chemotherapy. 'Data quality control' was assessed by comparison of data on case report forms (CRFs) with the corresponding items in the medical records. Eleven centres participating in the trial were visited by the same team of reviewers. Striking differences were noted in the chemotherapy administration procedures and between the type and quality of hospital files. Overall. there was an acceptable level of data quality and protocol compliance. Data accuracy was 81.8% (range: 65.6-97%) of the 4424 items checked. Incorrect data were found in 7.0% (2.3-14.5%), data were missing on the form in 3.6% of cases (0-12%) and data was on the form but not in the file in 7.6% of cases (0.7-17.5%). Causes of inaccuracy were analysed. Both problems in data management but also in a lack of clarity of the protocol and/or CRFs were to blame. Training and supervision of data managers, precision in writing protocols, standardisation of some aspects of CRFs and the use of a checklist for chemotherapy data and treatment toxicities would have avoided many of these errors. The need for QC in all collaborative groups performing MCT is emphasised. A literature review on QC in MCT dealing with chemotherapy is included. (C) 2000 Published by Elsevier Science Ltd. All rights reserved.
引用
下载
收藏
页码:1125 / 1133
页数:9
相关论文
共 50 条
  • [1] Health-related quality of life assessment in EORTC cancer clinical trials.
    Zikos, Efstathios
    Coens, Corneel
    Ediebah, Divine Ewane
    Quinten, Chantal
    Greimel, Eva
    Flechtner, Henning
    Taphoorn, Martin J. B.
    Reijneveld, Jaap
    Koller, Michael
    Bottomley, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [2] Participation of elderly gynecological cancer patients in clinical trials.
    Prieske, Katharina
    Trillsch, Fabian
    Oskay-Oezcelik, Gulten
    Chekerov, Radoslav
    Schoening, Eva -Maria
    Oliveira-Ferrer, Leticia
    Grimm, Donata
    Kuerti, Sasha
    Suling, Anna
    Schmalfeldt, Barbara
    Sehouli, Jalid
    Mahner, Sven
    Woelber, Linn Lena
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] Has health-related quality-of-life assessment in EORTC clinical trials helped to obtain regulatory approvals and change clinical practice? A review of the EORTC experience in cancer clinical trials.
    Zikos, Efstathios
    Coens, Corneel
    Sprangers, Miriam
    Greimel, Eva
    Ghislain, Irina
    Ediebah, Divine Ewane
    Flechtner, Henning
    Bottomley, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] WORKSHOP OF THE EORTC RADIOTHERAPY GROUP ON QUALITY ASSURANCE IN COOPERATIVE TRIALS OF RADIOTHERAPY - A RECOMMENDATION FOR EORTC COOPERATIVE GROUPS
    JOHANSSON, KA
    HANSON, WF
    HORIOT, JC
    RADIOTHERAPY AND ONCOLOGY, 1988, 11 (03) : 201 - 203
  • [5] TRIALS OF THE EORTC GASTROINTESTINAL-TRACT CANCER COOPERATIVE GROUP
    METZGER, U
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1986, 22 (03): : 359 - 359
  • [6] Reporting quality of abstracts in cancer clinical trials.
    Sivendran, Shanthi
    Newport, Kristina Braine
    Albert, Adam
    Galsky, Matt D.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] Economic evaluation alongside clinical trials. Methodological and practical issues. The EORTC experience
    Torfs, K
    EUROPEAN MEDICINES RESEARCH: PERSPECTIVES IN CLINICAL TRIALS, 1996, : 165 - 171
  • [8] Cooperative Group Cancer Clinical Trials: An NCIC Clinical Trials Group Perspective
    Meyer, Ralph M.
    Stanton, Heather A.
    Parulekar, Wendy R.
    Saad, Fred
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2011, 5 (06): : 379 - 381
  • [9] Locally-advanced breast cancer: the EORTC breast cancer cooperative group experience
    Piccart, MJ
    BREAST, 1997, 6 (05): : 319 - 319
  • [10] Predictive factors for response in advanced ovarian cancer: For the Translational Research Group of the EORTC-Gynecological Cancer Cooperative Group.
    Green, JA
    Anastasopoulou, A
    Duffaud, F
    Teodorovic, I
    van der Burg, M
    Berns, E
    van Diest, P
    Kenter, G
    Verheijen, R
    Vergote, I
    ANNALS OF ONCOLOGY, 2000, 11 : 85 - 86